Cerebrospinal Fluid IL-6, TNF-α and MCP-1 in Children with Acute Lymphoblastic Leukaemia during Chemotherapy

P. T. Protas; A. Holownia; K. Muszynska-Roslan; P. Wielgat; M. Krawczuk-Rybak; J. J. Braszko

doi:10.1055/s-0031-1295477

Neuropediatrics, Inhaltsverzeichnis

Neuropediatrics 2011; 42(06): 254-256
DOI: 10.1055/s-0031-1295477

Short Communication

Cerebrospinal Fluid IL-6, TNF-α and MCP-1 in Children with Acute Lymphoblastic Leukaemia during Chemotherapy

P. T. Protas

¹Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

,

A. Holownia

¹Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

,

K. Muszynska-Roslan

²Department of Paediatric Oncology, Medical University of Bialystok, Bialystok, Poland

,

P. Wielgat

¹Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

,

M. Krawczuk-Rybak

²Department of Paediatric Oncology, Medical University of Bialystok, Bialystok, Poland

,

J. J. Braszko

¹Department of Clinical Pharmacology, Medical University of Bialystok, Bialystok, Poland

› Institutsangaben

Abstract

The aim of the study was to investigate the levels of cerebrospinal fluid (CSF) cytokines during chemotherapy of acute lymphoblastic leukaemia (ALL). Examination of 12 ALL child (6 boys and 6 girls) patients evidenced significant increases in interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1) after induction treatment and significant increases in IL-6, tumour necrosis factor-α (TNF-α) and MCP-1 levels during the consolidation phase, as compared to their values at the time of diagnosis. There were no significant differences in CSF IL-6, TNF-α and MCP-1 concentrations after therapy. Our data suggest that standard ALL treatment may cause a subclinical inflammation and neurotoxicity.

Key words

acute lymphoblastic leukaemia - chemotherapy - IL-6 - MCP-1 - neurotoxicity - TNF-α

Volltext

Referenzen

References
1 Al-Gayyar MM, Eissa LA, Rabie AM et al. Measurements of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol 2007; 59: 409-417
2 Allan SM, Rothwell NJ. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci 2003; 358: 1669-1677
3 Battisti V, Maders LD, Bagatini MD et al. Measurement of oxidative stress and antioxidant status in acute lymphoblastic leukemia patients. Clin Biochem 2008; 41: 511-518
4 Cole PD, Kamen BA. Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. Ment Retard Dev Disabil Res Rev 2006; 12: 174-183
5 de Lemos ML, Monfared S, Denyssevych T et al. Evaluation of osmolality and pH of various concentrations of methotrexate, cytarabine, and thiotepa prepared in normal saline, sterile water for injection, and lactated Ringer’s solution for intrathecal administration. J Oncol Pharm Pract 2009; 15: 45-52
6 Eisenkraft A, Keidan I, Bielorai B et al. MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia. Leuk Res 2006; 30: 1259-1261
7 Ek T, Jarfelt M, Mellander L et al. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 2001; 37: 459-464
8 Iuvone L, Mariotti P, Colosimo C et al. Long-term cognitive outcome, brain computed tomography scan, and magnetic resonance imaging in children cured for acute lymphoblastic leukemia. Cancer 2002; 95: 2562-2570
9 Kadan-Lottick NS, Brouwers P, Breiger D et al. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2009; 27: 5986-5992
10 Kingma A, van Dommelen RI, Mooyaart EL et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001; 139: 413-420
11 Mazor D, Abucoider A, Meyerstein N et al. Antioxidant status in pediatric acute lymphocytic leukemia (ALL) and solid tumors: the impact of oxidative stress. Pediatr Blood Cancer 2008; 51: 613-615
12 Mazur B, Mertas A, Sońta-Jakimczyk D et al. Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. Hematol Oncol 2004; 22: 27-34
13 Müller-Hübenthal B, Azemar M, Lorenzen D et al. Tumor biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res 2009; 29: 4795-4805
14 Nathan PC, Wasilewski-Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 1065-1082
15 Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043
16 Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 2006; 142-146
17 Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49
18 Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009; 146: 489-503
19 Shuper A, Stark B, Kornreich L et al. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia. Isr Med Assoc J 2002; 4: 1050-1053
20 Vezmar S, Schüsseler P, Becker A et al. Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 2009; 52: 26-32